Flyer
Powerdoma™ Hybridoma Discovery Service
Powerdoma™ Hybridoma Antibody
Discovery Service
Upgrade the Conventional Hybridoma Technology
Accelerate the Generation of Diverse Antibodies
STREAMLINED PROCESS
Get Functional Antibody Sequences in
• Elimination of cumbersome two-month
subcloning steps for greater efficiency
• 3-4 months (Powerdoma™)vs 4-6
months (conventional hybridoma)
3 months
In vitro
Immunization
efficacy assy
FUNCTIONAL SCREENING IN ADVANCE
7 days
• High-throughput functional screening
based on hybridoma supernatant allows
earlier identification of functional binders
Plasma cell
enrichment
Cell
sequencing
IMPRESSIVE STATISTICS PROVEN
SUCCESS
7 days
Plasmid
Cell fusion
preparation
900+
60+
14+
7 days
hybridoma-based
projects
powerdomaTM
projects
in the clinical
stafe
HTP AB
384-well plate(plating
1-3 clones per well)
production
8-9 days
7 days
AB sample
~4,000/fusion
>90%
Monoclonal
count
Single sequence &
2 combinations
Binder
screening
Monoclonal
Function-Based Screening in Parallel to Quickly Deliver Lead
Antibodies
Antagonist assay
3
KD ELISA
Blockade of Target A mediated
signalling by RGA
1 0 0 0 0 0 0
9 0 0 0 0 0
8 0 0 0 0 0
7 0 0 0 0 0
6 0 0 0 0 0
5 0 0 0 0 0
4 0 0 0 0 0
3 0 0 0 0 0
2 0 0 0 0 0
1 0 0 0 0 0
0
2
1
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
M
M
K
M
1
1
1
1
1
1
1
1
1
S
S
S
S
S
S
S
S
S
n
n
n
S
S
S
S
S
S
S
S
S
0
6
6
.
0
0
K
1
M
K
B
M
M
B
B
Internalization
Signaling blockade
Sigalling blockade by RGA
1 5 0 0 0
1 0 0 0 0
5 0 0 0
0
Internalization assay on CHO-K1-hTAA
8 0
6 0
4 0
2 0
0
In te r n a liz a tio n r a te %
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
K
1
1
1
1
1
1
1
1
1
1
1
2
S
S
S
S
S
S
S
S
S
M
G
S
S
S
S
S
S
S
S
S
S
S
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
1
B
g
M
I
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
G
n
e
8
g
s
l
7
u
.
n
o
0
a
M
K
m
M
u
B
H
ProBioCDMO.com
+1-732-885-9188
Accelerating Ideas. Delivering Impact.
Case Study: Reporter Gene Assay (RGA) Using Powerdoma™
Supernatant
TIGIT/CD155 Blockade assay
TIGIT/CD155 blockade assay
6 0 0 0 0
4 0 0 0 0
2 0 0 0 0
0.3μ g /m L
B la n k
0
C
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
K
e
e
e
e
e
e
e
e
e
1
1
1
1
1
1
1
1
1
1
2
M
e
e
e
e
e
e
e
e
e
e
e
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
B
o
o
o
o
o
o
o
o
o
l
l
l
l
l
l
l
l
l
o
o
o
o
o
o
o
o
o
o
o
l
l
l
l
l
l
l
l
l
l
l
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
Figure A
Figure B
TIGIT reporter gene assay was conducted with
Powerdoma™ supernatant (figure A), identifying
four potential functional blockers (in green box),
and one non-functional binder (in red box). These
candidates were recombinantly expressed and
the purified Abs were subjected to full curve
blocking assays.
FACS Binding- CHO-
K1/Human TIGIT stable cells(+)
TIGIT Blockade bioassay on
Opt-TIGIT effector cell+ GS-
C2/CD155
As shown in figure B, these previously identified
functional blockers are confirmed to potently block
TIGIT/CD155 signaling, while the non-functional
binder (clone 10) binds to TIGIT (figure C) without
signal blockade (figure D).
Figure C
Figure D
Case Study: Faster to Get More Postive Antibody Sequences
with Powerdoma Platform
Screening funnel
Traditional
Hybridoma
PowerdomaTM
Hybridoma
Materials preparation, animal immunization
Plasma cell enrichment, cell fusion
11520 clones
12096 clones
50 positive binders
51 positive binders
ELISA screening by human/cyno/mouse
DLL3 protein
26 positive binders
45 positive binders
FACS screening by CHO-Human
DLL3
4 months
From Immunization
to sequence
2.5 months
From Immunization
to sequence
Sequencing and confirmation
13 positive binders
26 positive binders
10 positive binders
by IgG conversion
Lead Characterization:
FACS/SPR/Bioassay
5 positive binders
5 positive binders
Final leads
10 positive binders
Fast and efficient cell fusion and
the fused hybridoma is monoclonal
As fast as 1.5 month to
get positive sequence
More positive clones from
Powerdoma™ platform
Some binders showed higher affinity
FACS Binding-CHO-K1/human DLL3(+)
FACS Binding - DMS53